• 1. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Dimethoxybenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Methoxybenzenes Dimethoxybenzenes

Professional Introduction to N-(cyclopropylmethyl)-3,4-dimethoxyaniline (CAS No. 887588-08-1)

N-(cyclopropylmethyl)-3,4-dimethoxyaniline, identified by its Chemical Abstracts Service (CAS) number 887588-08-1, is a significant compound in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the class of aromatic amines, which have been widely studied for their diverse biological activities and potential therapeutic applications. The structural features of N-(cyclopropylmethyl)-3,4-dimethoxyaniline, particularly the presence of a cyclopropylmethyl group and methoxy substituents on the aniline ring, contribute to its unique chemical properties and biological interactions.

The cyclopropylmethyl group in the molecular structure of N-(cyclopropylmethyl)-3,4-dimethoxyaniline introduces a rigid three-membered ring that can influence the compound's spatial orientation and reactivity. This structural motif has been explored in various pharmacological contexts due to its ability to modulate binding affinities and metabolic stability. The methoxy groups at the 3 and 4 positions of the aniline ring further enhance the compound's hydrophobicity and electronic properties, making it a versatile scaffold for drug design.

In recent years, there has been growing interest in aromatic amines as potential candidates for treating various diseases, including cancer, neurodegenerative disorders, and infectious diseases. The unique structural features of N-(cyclopropylmethyl)-3,4-dimethoxyaniline have made it a subject of extensive research in medicinal chemistry. Studies have demonstrated that this compound can interact with biological targets such as enzymes and receptors, leading to potential therapeutic effects.

One of the most compelling aspects of N-(cyclopropylmethyl)-3,4-dimethoxyaniline is its potential as a lead compound for developing novel drugs. Researchers have leveraged its structural framework to design derivatives with enhanced pharmacological properties. For instance, modifications to the cyclopropylmethyl group or the methoxy substituents have been shown to improve bioavailability and target specificity. These findings highlight the importance of N-(cyclopropylmethyl)-3,4-dimethoxyaniline in drug discovery efforts.

The synthesis of N-(cyclopropylmethyl)-3,4-dimethoxyaniline involves multi-step organic reactions that require precise control over reaction conditions. Advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions and nucleophilic substitutions, have been employed to achieve high yields and purity. The efficiency of these synthetic routes is crucial for scaling up production and conducting further biological evaluations.

Evaluation of N-(cyclopropylmethyl)-3,4-dimethoxyaniline's biological activity has revealed promising results in preclinical studies. In vitro assays have shown that this compound exhibits inhibitory effects on certain enzymes and pathways relevant to disease progression. Additionally, preliminary in vivo studies suggest that it may have therapeutic potential in animal models of human diseases. These findings underscore the need for further investigation into its mechanisms of action and clinical efficacy.

The integration of computational chemistry and molecular modeling techniques has played a pivotal role in understanding the interactions between N-(cyclopropylmethyl)-3,4-dimethoxyaniline and biological targets. These tools have enabled researchers to predict binding affinities, optimize molecular structures, and identify potential drug candidates more efficiently. The combination of experimental data with computational insights provides a comprehensive approach to drug development.

In conclusion, N-(cyclopropylmethyl)-3,4-dimethoxyaniline (CAS No. 887588-08-1) strong>) represents a significant advancement in pharmaceutical chemistry. Its unique structural features and promising biological activities make it a valuable compound for drug discovery efforts. As research continues to uncover new therapeutic applications, this compound is poised to play a crucial role in developing innovative treatments for various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)